Abstract:Pulmonary fibrosis is a pathological manifestation of dysregulated cellular and molecular responses during injury, inflammation, and oxidative stress, progressing beyond recovery and culminating in the loss of alveoli (1). As a result, the gas exchange areas become occupied by activated myofibroblasts and the extracellular matrix they generate (i.e., collagen), most often in the distal areas of the lung. Pulmonary fibrosis is observed in multiple chronic interstitial lung diseases and as a sequela of acute respiratory distress syndrome. Idiopathic pulmonary fibrosis (IPF), the most common and perhaps devastating of the fibrosing interstitial lung diseases, occurs predominantly in the elderly (2). Of unknown etiology, IPF pathogenesis is considered to involve persistent microinjuries to the alveolar epithelium and a subsequent dysregulated injury-repair response that drives fibrosis (3). Decades of fibrosis research have identified multiple signaling pathways and protein complexes that play pivotal roles in the progressive expansion of fibrotic lung lesions in IPF. Although numerous promising therapeutic targets have been identified to attenuate lung fibrosis in preclinical studies, there remains no curative treatment for IPF (4). Thus, there is a need to identify druggable therapeutic targets that are safe and efficient to attenuate ongoing pulmonary fibrosis.

ASK1ng to Delay the Progression of Pulmonary Fibrosis